Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418575 | 1.00 | TACR1 (0.47) | TACR1RENPOLBMEN1KMT2A | |
| SCHEMBL416783 | 0.88 | CTSK (0.42) | POLBMAPTCTSKALDH1A1 | |
| SCHEMBL417751 | 0.88 | REN (0.46) | TACR1RENPOLBMEN1KMT2A | |
| SCHEMBL10261940 | 0.83 | REN (0.57) | RENPOLBACEMAPTCTSK | |
| SCHEMBL12011312 | 0.83 | REN (0.57) | RENPOLBACEMAPTCTSK | |
| SCHEMBL418576 | 0.77 | CTSK (0.40) | RENPOLBMAPTCTSKALDH1A1 | |
| SCHEMBL13318748 | 0.76 | POLB (0.49) | POLBMEN1KMT2AMAPTCTSK | |
| SCHEMBL417748 | 0.76 | POLB (0.49) | POLBMEN1KMT2AMAPTCTSK | |
| SCHEMBL13085451 | 0.76 | NPSR1 (0.51) | RENACE | |
| SCHEMBL464310 | 0.75 | NPSR1 (0.50) | RENACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | TACR1 900/4885REN 2419/4885POLB 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.